These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34213123)

  • 21. Controllable production of low molecular weight heparins by combinations of heparinase I/II/III.
    Wu J; Zhang C; Mei X; Li Y; Xing XH
    Carbohydr Polym; 2014 Jan; 101():484-92. PubMed ID: 24299802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety profile of different low-molecular weight heparins used at therapeutic dose.
    Gouin-Thibault I; Pautas E; Siguret V
    Drug Saf; 2005; 28(4):333-49. PubMed ID: 15783242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-activity relationships of low molecular weight heparins expose to the risk of achieving inappropriate targets in patients with renal failure.
    Stratta P; Karvela E; Canavese C; Quaglia M; Lazzarich E; Fenoglio R; Pergolini P; Bellomo G; Cena T; Magnani C
    Curr Med Chem; 2009; 16(23):3028-40. PubMed ID: 19689280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low molecular weight heparins and their clinical applications.
    Hao C; Sun M; Wang H; Zhang L; Wang W
    Prog Mol Biol Transl Sci; 2019; 163():21-39. PubMed ID: 31030749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism.
    Ornstein DL; Hong-Dice YG; Papini JR
    Mil Med; 2001 Jul; 166(7):593-601. PubMed ID: 11469031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rational design of low-molecular weight heparins with improved in vivo activity.
    Sundaram M; Qi Y; Shriver Z; Liu D; Zhao G; Venkataraman G; Langer R; Sasisekharan R
    Proc Natl Acad Sci U S A; 2003 Jan; 100(2):651-6. PubMed ID: 12525684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor xa activity as a pharmaceutical mechanism and a yardstick for therapy.
    Béguin S; Welzel D; Al Dieri R; Hemker HC
    Haemostasis; 1999; 29(2-3):170-8. PubMed ID: 10629396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New data on the pharmacology of heparin and low molecular weight heparins.
    Samama MM; Bara L; Gouin-Thibault I
    Drugs; 1996; 52 Suppl 7():8-14; discussion 14-5. PubMed ID: 9042555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Hirsh J; Bauer KA; Donati MB; Gould M; Samama MM; Weitz JI
    Chest; 2008 Jun; 133(6 Suppl):141S-159S. PubMed ID: 18574264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heparins, low-molecular-weight heparins, and other glycosaminoglycans analyzed by agarose gel electrophoresis and azure A-silver staining.
    Wang L; Malsch R; Harenberg J
    Semin Thromb Hemost; 1997; 23(1):11-6. PubMed ID: 9156405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heparin-Binding Copolymer as a Complete Antidote for Low-Molecular-Weight Heparins in Rats.
    Kalaska B; Miklosz J; Kamiński K; Swieton J; Jakimczuk A; Yusa SI; Pawlak D; Nowakowska M; Szczubiałka K; Mogielnicki A
    J Pharmacol Exp Ther; 2020 Apr; 373(1):51-61. PubMed ID: 31937564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
    Martineau P; Tawil N
    Ann Pharmacother; 1998 May; 32(5):588-98, 601. PubMed ID: 9606481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of inhibitory potency of argatroban toward thrombin by electrophoretically mediated microanalysis.
    Pochet L; Servais AC; Farcas E; Bettonville V; Bouckaert C; Fillet M
    Talanta; 2013 Nov; 116():719-25. PubMed ID: 24148466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low molecular weight heparins.
    Harris LF; Castro-López V; Hammadi N; O'Donnell JS; Killard AJ
    Talanta; 2010 Jun; 81(4-5):1725-30. PubMed ID: 20441964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experiences with low-molecular weight heparins in pediatric patients.
    Hofmann S; Knoefler R; Lorenz N; Siegert G; Wendisch J; Mueller D; Taut-Sack H; Dinger J; Kabus M
    Thromb Res; 2001 Sep; 103(5):345-53. PubMed ID: 11553367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases.
    Agnelli G; Iorio A; Renga C; Boschetti E; Nenci GG; Ofosu FA; Hirsh J
    Circulation; 1995 Nov; 92(10):2819-24. PubMed ID: 7586247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delayed-type hypersensitivity and cross-reactivity to heparins and danaparoid: a prospective study.
    Grassegger A; Fritsch P; Reider N
    Dermatol Surg; 2001 Jan; 27(1):47-52. PubMed ID: 11231243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Issues in the utilization of low molecular weight heparins.
    O'Shea SI; Ortel TL
    Semin Hematol; 2002 Jul; 39(3):172-8. PubMed ID: 12124679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A simple capillary electrophoresis method for the rapid separation and determination of intact low molecular weight and unfractionated heparins.
    Patel RP; Narkowicz C; Hutchinson JP; Hilder EF; Jacobson GA
    J Pharm Biomed Anal; 2008 Jan; 46(1):30-5. PubMed ID: 18024047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An assessment of polydispersed species in unfractionated and low molecular weight heparins by diffusion ordered nuclear magnetic resonance spectroscopy method.
    Bednarek E; Sitkowski J; Bocian W; Mulloy B; Kozerski L
    J Pharm Biomed Anal; 2010 Nov; 53(3):302-8. PubMed ID: 20417048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.